{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:51:08Z","timestamp":1786989068229,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001825","name":"Danish Agency for Science and Higher Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008361","name":"Scleroseforeningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008361","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.expneurol.2013.02.005","type":"journal-article","created":{"date-parts":[[2013,2,20]],"date-time":"2013-02-20T00:03:46Z","timestamp":1361318626000},"page":"744-747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Neuromyelitis optica-like pathology is dependent on type I interferon response"],"prefix":"10.1016","volume":"247","author":[{"given":"Reza","family":"Khorooshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Wlodarczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrin","family":"Asgari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2013.02.005_bb0005","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1600-0404.2010.01416.x","article-title":"Neuromyelitis optica (NMO)\u2014an autoimmune disease of the central nervous system (CNS)","volume":"123","author":"Asgari","year":"2011","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.expneurol.2013.02.005_bb0010","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jneuroim.2012.09.010","article-title":"Complement-dependent pathogenicity of brain-specific antibodies in cerebrospinal fluid","volume":"254","author":"Asgari","year":"2013","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.expneurol.2013.02.005_bb0015","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.it.2011.03.008","article-title":"Interferon-beta exacerbates Th17-mediated inflammatory disease","volume":"32","author":"Axtell","year":"2011","journal-title":"Trends Immunol."},{"key":"10.1016\/j.expneurol.2013.02.005_bb0020","doi-asserted-by":"crossref","first-page":"pe70","DOI":"10.1126\/stke.4162007pe70","article-title":"Type I interferons as anti-inflammatory mediators","volume":"2007","author":"Benveniste","year":"2007","journal-title":"Sci. STKE"},{"key":"10.1016\/j.expneurol.2013.02.005_bb0025","doi-asserted-by":"crossref","first-page":"7835","DOI":"10.1073\/pnas.0602460103","article-title":"Neurons produce type I interferon during viral encephalitis","volume":"103","author":"Delhaye","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2013.02.005_bb0030","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1128\/JVI.01794-07","article-title":"Type I interferons are essential in controlling neurotropic coronavirus infection irrespective of functional CD8 T cells","volume":"82","author":"Ireland","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.expneurol.2013.02.005_bb0035","doi-asserted-by":"crossref","first-page":"11223","DOI":"10.1128\/JVI.01093-12","article-title":"Visualizing production of beta interferon by astrocytes and microglia in brain of la crosse virus-infected mice","volume":"86","author":"Kallfass","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.expneurol.2013.02.005_bb0040","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.4049\/jimmunol.0901753","article-title":"Injury-induced type I IFN signaling regulates inflammatory responses in the central nervous system","volume":"185","author":"Khorooshi","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.expneurol.2013.02.005_bb0045","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1177\/1352458512439439","article-title":"Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?","volume":"18","author":"Kim","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.expneurol.2013.02.005_bb0050","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.expneurol.2013.02.005_bb0055","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2013.02.005_bb0060","doi-asserted-by":"crossref","first-page":"7514","DOI":"10.1128\/JVI.79.12.7514-7527.2005","article-title":"Differential regulation of interferon regulatory factor (IRF)-7 and IRF-9 gene expression in the central nervous system during viral infection","volume":"79","author":"Ousman","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.expneurol.2013.02.005_bb0065","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/archneurol.2010.188","article-title":"Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers","volume":"67","author":"Palace","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.expneurol.2013.02.005_bb0070","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.molmed.2010.06.001","article-title":"New lessons about old molecules: how type I interferons shape Th1\/Th17-mediated autoimmunity in the CNS","volume":"16","author":"Prinz","year":"2010","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.expneurol.2013.02.005_bb0075","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.immuni.2008.03.011","article-title":"Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system","volume":"28","author":"Prinz","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.expneurol.2013.02.005_bb0080","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/brain\/awl371","article-title":"Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis","volume":"130","author":"Roemer","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2013.02.005_bb0085","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awp309","article-title":"Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice","volume":"133","author":"Saadoun","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2013.02.005_bb0090","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ana.22686","article-title":"Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain","volume":"71","author":"Saadoun","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2013.02.005_bb0095","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/WNL.0b013e3181f8832e","article-title":"IFNbeta-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum","volume":"75","author":"Shimizu","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2013.02.005_bb0100","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000227277","article-title":"Interferon-beta(1b) treatment in neuromyelitis optica","volume":"62","author":"Tanaka","year":"2009","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.expneurol.2013.02.005_bb0105","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.4049\/jimmunol.170.9.4776","article-title":"IFN-beta gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis","volume":"170","author":"Teige","year":"2003","journal-title":"J. Immunol."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488613000587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488613000587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:47:12Z","timestamp":1762148832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488613000587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":21,"alternative-id":["S0014488613000587"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2013.02.005","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuromyelitis optica-like pathology is dependent on type I interferon response","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2013.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}